Although serologic tests have proved to be very useful in the diagnosis of histoplasmosis, they have certain limitations. One of these limitations is false-positive results for patients with other diseases (5, 11, 12, 15, 19, 20, 27, 28, 30, 46) . A number of factors could lead to such results, one of which is the presence of cross-reacting antigens in the reagents used for serodiagnosis. False-positive results have been attributed to* the presence of antigens cross-reactive between Histoplasma capsulatum and other fungal pathogens (5, 27, 46) . Furthermore, analysis of antigenic components of H. capsulatum and other fungal pathogens showed that the crude antigenic preparations used in fungal serodiagnosis might contain one or more common antigens (5, 11-13, 15, 16, 18-20, 23, 27, 28, 30, 32, 37, 46) .
In the serodiagnosis of histoplasmosis, histoplasmin (the culture filtrate of the mycelial form of H. capsulatum) is one of the most widely used reagents. In attempts to minimize the degree of cross-reactivity, histoplasmin has been partially purified and characterized (2, 4, 22, 25, 40, 41) . However, none of these studies showed that the purified reagent was specific for H. capsulatum.
H. capsulatum and other fungal pathogens share a number of cell wall and cytoplasmic antigenic determinants (1, 6, 8, 9, 21, 31) . H. capsulatum may also contain unique components that are not shared with other organisms. Monoclonal antibody (MAb) technology has proved useful in identifying single antigenic determinants (epitopes), even in complex mixtures. This technology has also been used recently for the production of MAbs against histoplasmin (33) , Candida albicans (26, 29, 36, 42) , Blastomyces dermatitidis (50) , and Cryptococcus neoformans (7, 10) .
MAbs might be useful for identification of specific Histoplasma antigens which could be used to improve the specificity of the serologic tests, as well as for identification of the cell-mediated immune responses in histoplasmosis. Herein we report our findings on the preparation and characterization of four MAbs against H. capsulatum yeast cell antigens.
* Corresponding author.
MATERIALS AND METHODS
Antigens. A whole yeast cell extract of H. capsulatum G217B was prepared as previously described (44) . In brief, yeast cells were grown in brain heart infusion broth (Difco Laboratories, Detroit, Mich.) supplemented with 1% glucose. Flasks were incubated at 37°C on a Gyrotory shaker (New Brunswick Scientific Co., Inc., New Brunswick, N.J.) with a shaking speed of 150 rpm. The yeast cell cultures were centrifuged and washed twice in 0.02 M Tris hydrochloride buffer (pH 7.5) at 4°C. The packed cells were suspended in equal volumes of 0.1 M Tris hydrochloride buffer (pH 7.8) and transferred to a Braun homogenizer glass bottle (B. Braun Co., Helsungen, Federal Republic of Germany) containing an equal amount of acid-washed glass beads (diameter 0.45 to 0.55 mm). The cells were broken in the Braun homogenizer by shaking for two 1-min periods. Unbroken cells and debris were removed by centrifuging the suspension at 20,000 x g for 20 min. The supernatant was collected, and the pellet was resuspended in the same buffer and centrifuged at 30,000 x g for 30 min. The two supernatants were pooled to make the H. capsulatum whole yeast cell extract.
The yeast form of clinical isolates of B. dermatitidis, C. albicans, C. neoformans, Sporothrix schenckii, and H. capsulatum G217B, A811 (from the Centers for Disease Control, Atlanta, Ga.), and P-IN (isolate from Indianapolis, Ind.) were grown in brain heart infusion broth supplemented with 1% glucose. Flasks were incubated in the Gyrotory shaker for 48 h at 37°C and 150 rpm. Cells were harvested by centrifugation at 8,000 x g for 15 min and washed twice in normal saline. The cells were killed by incubation with 3.7% Formalin at 25°C for 24 h and washed in normal saline, and the nonviability was verified by culture at 37°C on brain heart infusion agar for 72 h. A 10% suspension of the killed cells was suspended with an equal volume of glass beads in normal saline and sonicated in an ultrasonicator (Model U-20; Blackstone Corp., Jamestown, N.Y.) for 4 to 6 h. Soluble whole yeast cell extracts were prepared by centri- in Freund incomplete adjuvant (Difco) and on day 14 with 0.5 ml of the extract in sterile saline. On day 21, the mice were bled and the sera were tested by enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay for antibody against a soluble yeast cell extract of H. capsulatum G217B. If the sera were positive, the mice were boosted intraperitoneally on day 28 with 0.5 ml of the extract (100 ,ug of protein per mouse) in normal saline, and on day 32 the mouse spleen cells were used for fusion.
Spleen cells from mice with elevated levels of antibodies to H. capsulatum were fused with Sp2/0 myeloma cells in the log phase in a ratio of 10:1, using 45% polyethylene glycol (J. T. Baker Chemical Co., Phillipsburg, N.J.) as described by Zola and Brooks (51) . The fused cells were plated into 96-well plates and incubated at 37°C in 7% CO2. Initial screening for antibody activity against H. capsulatum whole yeast cell extract was done 14 to 16 days after fusion by using a solid-phase radioimmunoassay. In this assay, rabbit anti-mouse immunoglobulin G (IgG) plus IgM (Accurate Chemical and Scientific Corp., Westbury, N.Y.) were used, followed by 1251I-labeled protein A. Positive hybridomas were cloned twice by the limiting dilution method. MAbs were produced in large quantities in 75-cm2 tissue culture flasks and in mouse ascitic fluid. The MAbs were then purified by ammonium sulfate precipitation and/or affinity chromatography, using carbodiimide (CDI)-activated agarose CL-6B (Pierce Chemical Co., Rockford, Ill.) charged with rabbit anti-mouse immunoglobulins (Accurate Chemical and Scientific). The MAbs were eluted with 100 mM H3PO4-Na2HPO4 buffer (pH 2.7).
Solid-phase radioimmunoassay. Polystyrene, flat-bottom 96-well plates were coated with 0.1 ml of the desired antigen in 0.01 M Tris hydrochloride (pH 7.0). Unbound sites were blocked with 0.1 ml of 5% bovine serum albumin (BSA) in 0.01 M Tris hydrochloride (pH 7.0). Next, 0.1 ml of the test antibody diluted in 5% BSA in 0.1 M Tris-saline (pH 8.0) was added to the wells. Wells receiving antibodies reactive with the solid-phase antigen were identified by adding 0. counter. All specimens were tested in triplicate. ELISA. A H. capsulatum whole yeast cell extract (0.1 ml containing 100 ,ug of protein) in 0.1 M Na2CO3 buffer (pH 9.6) was added to each well of a 96-well plate. Unbound sites in each well were blocked with 0.1 ml of 5% BSA in 0.01 M Tris hydrochloride buffer (pH 7.0). Next, the test antibody suspension (0.1 ml) in 5% BSA in 0.1 M Tris-saline buffer (pH 8.0) was dispensed into each well. A 1/40 dilution of alkaline phosphatase-conjugated anti-mouse immunoglobulin (Accurate Chemical and Scientific) in 0.1 M Tris-saline buffer in 5% BSA (pH 8.0) was dispensed into each well. Finally, a 0.1-ml portion of p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, Mo.; 1 mg/ml in Na2CO3 buffer, pH 9.2) was dispensed into each well. For each step, plates were incubated at 37°C for 1 h, aspirated, and washed three times with phosphate-buffered saline-Tween 20. Reactivity was measured spectrophotometrically with a microplate MR 600 automatic ELISA reader (Dynatech Instruments, Inc., Torrance, Calif.). All samples were tested in triplicate.
Western protein blotting (immunoblotting). Immunoblotting was performed as described by Batteiger et al. (3), based on modification of earlier procedures of Laemmli (24) . In brief, separation gels (9 by 14 by 0.15 cm) containing 10% acrylamide, 0.375 M Tris hydrochloride (pH 8.8), and 0.1% sodium dodecyl sulfate were prepared in a Bio-Rad slab gel apparatus (Model 220). Proteins (antigens) were solubilized in 1.5% (wt/vol) sodium dodecyl sulfate-1.25% (vol/vol) 2-mercaptoethanol-1.25% (vol/vol) glycerol in 2.5 mM Tris hydrochloride (pH 6.8). The solubilization mixtures were incubated at 100°C for 10 min and cooled to 25°C. Antigenic extracts were standardized to contain 20 jxg of protein per ml per lane. Electrophoresis conditions were those described by Batteiger et al. (3) . Each strip was incubated with 125I-labeled protein A (95,000 cpm per strip).
Subtyping of the MAbs. The subtyping of the MAbs against H. capsulatum was performed as specified in the instructions of a commercially available kit (ICN Immunologicals, Lisle, Ill.). In brief, rabbit anti-mouse IgGl, IgG2a, IgG2b, IgG3, and IgM were placed into the peripheral wells of a seven-well immunodiffusion plate. The MAb to be tested was placed in the central well. The plates were incubated at 25°C for 48 h. All tests were performed in triplicate, and all MAbs were tested at least twice.
RESULTS
Immunoglobulin class and subclass of MAbs. Two fusions between the Sp2/0 myeloma cell line and spleen cells from female BALB/c mice immunized with soluble whole yeast cell extract of H. capsulatum G217B resulted in the production of four MAbs against H. capsulatum which were obtained from four hybrid cell lines. The immunoglobulin class and subclass of these four MAbs were determined by immunodiffusion, using a commercially available kit, as described above. They belonged to three subclasses: MAb C. immitis, C. neoformans, H. capsulatum (strains G217B, A811, and P-IN), P. brasiliensis, S. schenckii, and Mycobacterium tuberculosis were prepared as described above. The reactivity of different dilutions of these antigenic preparations was verified by solid-phase radioimmunoassay with homologous sera from rabbits immunized with fungal and mycobacterial pathogens. Optimal dilutions were selected to test the specificity of the four MAbs in solid-phase radioimmunoassay. Pathogens used were divided into three groups. Group 1 consisted of closely related fungal pathogens: H. capsulatum, B. dermatitidis, C. immitis, and P. brasiliensis. Group 2 consisted of other fungal pathogens: A. fumigatus, C. albicans, C. neoformans, and S. schenckii. Group 3 consisted of M. tuberculosis. To simplify and standardize the reactivity of the four MAbs, a reactivity index was developed. The reactivity index was calculated by dividing the reactivity (cpm) of the MAb with an antigen by the reactivity (cpm) of the same MAb with the no-antigen control. A reactivity index greater than twice that of the no-antigen control was considered positive. Antibody activity of MAbs against H. capsulatum was not determined by titration but rather by testing a single concentration. Also, standardization to allow accurate quantitation of antibody content was not performed. Thus, the immunoglobulin concentrations of different MAb preparations or activity of a single MAb against different antigens could not be precisely determined. Nevertheless, in our experience, measurements of antibody activity based on results of testing a single dilution correlate well with endpoint antibody titers and probably provide a semiquantitative assessment of antibody activity. The reactivity indices of MAbs 1 and 2, which showed positive indices only with the yeast cell antigens of H. capsulatum (reactivity indices, 92 and 17, respectively) and B. dermatitidis (reactivity indices, 16 and 22, respec- tively), are shown in Table 1 . Both MAbs showed negative reactivity indices (0.6 to 2) with the other pathogens.
The reactivity indices of MAbs 3 and 4 are shown in Table  2 . MAb 3 showed positive reactivity indices only with the yeast forms of H. capsulatum, B. dermatitidis, C. albicans, P. brasiliensis, and S. schenckii, whereas MAb 4 had positive reactivity indices with the yeast antigens of H. capsulatum (index, 52) and B. dermatitidis (index, 8), the mycelial antigen of C. immitis (index, 4), the yeast and mycelial antigens of C. albicans (indices, 12 and 6, respectively), the mycelial antigen of A. fumigatus (index, 4), and the tuberculin antigen of M. tuberculosis (index, 3). MAbs 1 and 2 were more specific to H. capsulatum antigens than the broadly cross-reacting MAbs 3 and 4.
Reactivity of MAbs against different strains of H. capsulatum. For partial evaluation of the strain or serotype specificity of the MAbs prepared against H. capsulatum, their reactivity with antigens from three different H. capsulatum strains was tested in solid-phase radioimmunoassay. All (36) .
In conclusion, four MAbs against the yeast antigen of H. capsulatum were prepared and characterized. Unique features of these antibodies indicate that they recognize different epitopes and may demonstrate some degree of serotype specificity. MAbs 1 and 2 showed more specificity to H. capsulatum, as they cross-reacted only with the yeast antigen of B. dermatitidis. MAbs 3 and 4 showed broader cross-reactivity. MAbs may prove useful in the development of more specific immunodiagnostic tests for histoplasmosis.
